ProCE Banner Activity

Considerations With Androgen-Deprivation Therapy for Castration-Sensitive Prostate Cancer

Clinical Thought

In this commentary, Daniel Saltzstein, MD, shares his thoughts on important considerations for ADT from his live presentation on optimally caring for patients with CSPC across the spectrum of disease.

Released: October 02, 2023

Share

Faculty

Daniel Saltzstein

Daniel Saltzstein, MD

Medical Director of Research
Director of the Advanced Therapeutic Clinic
Urology San Antonio
Clinical Assistant Professor
The University of Texas Health Science Center at San Antonio
San Antonio, Texas 

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Myovant Sciences and Pfizer, Inc.

Myovant Sciences

Pfizer, Inc.

Disclosure

Primary Author

Daniel Saltzstein, MD

Medical Director of Research
Director of the Advanced Therapeutic Clinic
Urology San Antonio
Clinical Assistant Professor
The University of Texas Health Science Center at San Antonio
San Antonio, Texas 

Daniel Saltzstein, MD: consultant/advisor/speaker: Dendreon, Janssen, Lantheus, Myovant.